Gadducci, A., E. Sartori, et al. (1998) . "Analysis of failures after negative second- look in patients with advanced ovari an cancer: an Italian multicenter study." Gynecol Oncol 68(2): 150-5. 63. Geissmann, F., P. Revy, et al. (1999) . "TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells." J Immunol 162(8): 4567-75. Protocol # CL-PTL 105 CONFIDENTIAL AM #9 09/25/15 Page 82 64. Germain, R. N. (1994). "MHC- dependent antigen processing and peptide presentation: providin g ligands for T lymphocyte activation." Cell 76(2): 287-99. 65. Gilboa, E., S. K. Nair, et al. (1998). "Immunotherapy of cancer with dendritic-cell- based vaccines." Cancer Immunol Immunother 46(2): 82-7. 66. Graycar, J. L., D. A. Miller, et al. (1989). "Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-bet a 1 and -beta 2." Mol Endocrinol 3(12): 1977- 86. 67. Hanahan, D. and R. A. Weinberg (2000). "The hallmarks of cancer." Cell 100(1): 57-70. 68. Haynes, N. M., R. G. van der Mos t, et al. (2008). "Immunogenic anti-cancer chemotherapy as an emerging concept." Curr Opin Immunol 20(5): 545-57. 69. Heintz, A. P., F. Odicino, et al. (2 006). "Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Tr eatment in Gynecological Cancer." Int J Gynaecol Obstet 95 Suppl 1 : S161-92. 70. Heldin, C. H., K. Miyaz ono, et al. (1997). "TGF-b signaling from cell membrane to nucleus through SMAD proteins." Nature 390: 465-471. 71. Henrich, S., A. Cameron, et al. (2003) . "The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. " Nat Struct Biol 10(7): 520-6. 72. Henriksen, R., A. Gobl, et al. (1995) . "Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 bind ing protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms." Lab Invest 73(2): 213-20. 73.